KALA BIO, Inc. (KALA) stock
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.43−0.40 (-10.44%)
Close on Nov 17, 2026Market cap $66.34MP/E –Yield –
Kala Bio total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Kala Bio's total debt was $28.41M at Sep 30, 2025. For fiscal 2024 it was $30.44M, down 11.0% from the year before. The highest annual figure on record is $78.93M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $30.44M | -11.0% |
| FY2023 | Dec 31, 2023 | $34.19M | -20.4% |
| FY2022 | Dec 31, 2022 | $42.94M | -45.6% |
| FY2021 | Dec 31, 2021 | $78.93M | +9.3% |
| FY2020 | Dec 31, 2020 | $72.24M | +1.5% |
| FY2019 | Dec 31, 2019 | $71.18M | +1.4% |
| FY2018 | Dec 31, 2018 | $70.23M | +276.5% |
| FY2017 | Dec 31, 2017 | $18.65M | +93.2% |
| FY2016 | Dec 31, 2016 | $9.65M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $28.41M | -19.1% |
| Q2 FY2025 | Jun 30, 2025 | $28.30M | -18.7% |
| Q1 FY2025 | Mar 31, 2025 | $30.62M | -11.2% |
| Q4 FY2024 | Dec 31, 2024 | $30.44M | -11.0% |
| Q3 FY2024 | Sep 30, 2024 | $35.14M | +3.7% |
| Q2 FY2024 | Jun 30, 2024 | $34.82M | +3.7% |
| Q1 FY2024 | Mar 31, 2024 | $34.50M | +3.7% |
| Q4 FY2023 | Dec 31, 2023 | $34.19M | -20.4% |
| Q3 FY2023 | Sep 30, 2023 | $33.88M | -20.6% |
| Q2 FY2023 | Jun 30, 2023 | $33.57M | -57.9% |
| Q1 FY2023 | Mar 31, 2023 | $33.27M | -58.1% |
| Q4 FY2022 | Dec 31, 2022 | $42.94M | -45.6% |
| Q3 FY2022 | Sep 30, 2022 | $42.64M | -45.7% |
| Q2 FY2022 | Jun 30, 2022 | $79.80M | +2.2% |
| Q1 FY2022 | Mar 31, 2022 | $79.36M | +9.4% |
| Q4 FY2021 | Dec 31, 2021 | $78.93M | +9.3% |
| Q3 FY2021 | Sep 30, 2021 | $78.49M | +9.1% |
| Q2 FY2021 | Jun 30, 2021 | $78.06M | +8.9% |
| Q1 FY2021 | Mar 31, 2021 | $72.52M | +1.5% |
| Q4 FY2020 | Dec 31, 2020 | $72.24M | +1.5% |
| Q3 FY2020 | Sep 30, 2020 | $71.97M | +1.5% |
| Q2 FY2020 | Jun 30, 2020 | $71.70M | +1.4% |
| Q1 FY2020 | Mar 31, 2020 | $71.44M | +1.4% |
| Q4 FY2019 | Dec 31, 2019 | $71.18M | +1.4% |
| Q3 FY2019 | Sep 30, 2019 | $70.94M | +258.5% |
| Q2 FY2019 | Jun 30, 2019 | $70.69M | +257.6% |
| Q1 FY2019 | Mar 31, 2019 | $70.46M | +256.8% |
| Q4 FY2018 | Dec 31, 2018 | $70.23M | +276.5% |
| Q3 FY2018 | Sep 30, 2018 | $19.79M | +0.2% |
| Q2 FY2018 | Jun 30, 2018 | $19.77M | +103.6% |
| Q1 FY2018 | Mar 31, 2018 | $19.75M | +104.5% |
| Q4 FY2017 | Dec 31, 2017 | $18.65M | – |
| Q3 FY2017 | Sep 30, 2017 | $19.74M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.71M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.65M | – |
See a number that looks wrong?